Opthea Limited Showcases at Ophthalmology Event
Company Announcements

Opthea Limited Showcases at Ophthalmology Event

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited, a biopharmaceutical company focused on innovative therapies for retinal diseases, will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Their lead product candidate, sozinibercept, is currently in two pivotal Phase 3 clinical trials aimed at improving treatment outcomes for wet age-related macular degeneration. The event will feature a presentation by CEO Frederic Guerard and offer investor meetings to discuss the company’s advancements.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOpthea Limited Strengthens Leadership and Advances AMD Treatment
TheFlyOpthea executive director Megan Baldwin to retire from board
TipRanks Auto-Generated NewsdeskOpthea Advances Retinal Disease Treatments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App